Pluijmert Niek J, de Jong Rob C M, de Vries Margreet R, Pettersson Knut, Atsma Douwe E, Jukema J Wouter, Quax Paul H A
Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
JACC Basic Transl Sci. 2020 Dec 2;5(12):1228-1239. doi: 10.1016/j.jacbts.2020.09.012. eCollection 2020 Dec.
Phosphorylcholine monoclonal immunoglobulin G antibody attenuates the immediate post-ischemic inflammatory response by reducing the proinflammatory chemokine (C-C motif) ligand 2 chemokine and circulating Ly-6C monocytes. This subsequently enhances the post-ischemic repair process, resulting in limited adverse cardiac remodeling and preservation of cardiac function. Therefore, phosphorylcholine monoclonal immunoglobulin G antibody therapy may be a valid therapeutic approach against myocardial ischemia-reperfusion injury.
磷酰胆碱单克隆免疫球蛋白G抗体通过减少促炎趋化因子（C-C基序）配体2趋化因子和循环中的Ly-6C单核细胞，减轻缺血后即刻的炎症反应。这随后增强了缺血后的修复过程，导致不良心脏重塑受限并保留心脏功能。因此，磷酰胆碱单克隆免疫球蛋白G抗体治疗可能是一种针对心肌缺血-再灌注损伤的有效治疗方法。
